Drug granule coatings that impart smear resistance during mechanical compression

• US 20050175696A1
• Filed: 12/28/2004
• Published: 08/11/2005
• Est. Priority Date: 12/29/2003
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Qureshi, Abdul Majid, Ergun, James, Ramachandran, Satishkumar, Khan, Alya, Edgren, David, Yam, Noymi
• Application Number:
  US11/024,329
• Publication Number:
  US 20050175696A1
• Time in Patent Office: Days
• US Class Current: 424/470
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

A drug formulation is disclosed comprising granules having a substrate and a coating, said granule substrate comprising a solubilizing surfactant or a low solubility therapeutic drug, or both, and said granule coating comprising a hydrophilic polymer. Also disclosed is a drug formulation consisting of a tablet core made by mechanical compression, wherein said tablet core comprises granules having a substrate and a coating, said granule substrate comprising a solubilizing surfactant or a low solubility therapeutic drug, or both, and said granule coating comprising a hydrophilic polymer. Also disclosed is a dosage form for oral administration of topiramate, comprising a tablet core and an osmotic delivery system. Methods for controlling topiramate release patterns by altering the composition of the topiramate dosage form are also disclosed.

Claims

1. A drug formulation comprising granules having a substrate and a coating, said granule substrate comprising a solubilizing agent or a low solubility therapeutic drug, or both, and said granule coating comprising a hydrophilic polymer.

2. A drug formulation as in claim 1, wherein the granule substrate comprises a solubilizing agent.

3. A drug formulation as in claim 2, wherein the solubilzing agent is a surfactant.

4. A drug formulation as in claim 3, wherein the granule substrate comprises a low solubility therapeutic drug.

5. A drug formulation as in claim 4, wherein the low solubility therapeutic drug is topiramate.

6. A drug formulation as in claim 4, wherein the amount of surfactant is between about 5% and about 50% by weight of the core.

7. A drug formulation as in claim 4, wherein the surfactant is selected from the group consisting of polyoxyl 40 stearate, polyoxyl 50 stearate, triblock co-polymers of ethylene oxide/propylene oxide/ethylene oxide, sorbitan monopalmitate, sorbitan monostearate, glycerol monostearate, polyoxyethlene stearate, polyoxyethylene 40 sorbitol lanolin derivative, polyoxyethylene 75 sorbitol lanolin derivative, polyoxyethylene 6 sorbitol beeswax derivative, polyoxyethylene 20 sorbitol beeswax derivative, polyoxyethylene 20 sorbitol lanolin derivative, polyoxyethylene 50 sorbitol lanolin derivative, polyoxyethylene 23 lauryl ether, polyoxyethylene 23 lauryl ether, polyoxyethylene 2 cetyl ether, polyoxyethylene 10 cetyl ether, polyoxyethylene 20 cetyl ether, polyoxyethylene 2 stearyl ether, polyoxyethylene 10 stearyl ether, polyoxyethylene 20 stearyl ether, polyoxyethylene 21 stearyl ether, polyoxyethylene 20 oleyl ether, polyoxyethylene 40 stearate, polyoxyethylene 50 stearate, polyoxyethylene 100 stearate, sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, polyoxyethylene 4 sorbitan monostearate, polyoxyethylene 20 sorbitan tristearate and mixtures thereof.

8. A drug formulation as in claim 7, wherein the surfactant is selected from the group consisting of polyoxyl 40 stearate, polyoxyl 50 stearate, di-block copolymers of ethylene oxide:

propylene oxide, and a;

b;

a triblock copolymers of ethylene oxide;

propylene oxide;

ethylene oxide.

9. A drug formulation as in claim 4, wherein the low solubility therapeutic drug in the absence of solubilizing agent has an aqueous solubility between about 1 μ

g/ml and about 50 mg/ml.

10. A drug formulation as in claim 1, wherein the granule coating is continuous.

11. A drug formulation as in claim 1, wherein the granule coating is water-soluble.

12. A drug formulation as in claim 11, wherein the hydrophillic polymer is selected from the group consisting of polyvinyl pyrrolidone, polyethylene oxide, polyethylene glycol, polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol copolymer, vinyl acetate-vinyl pyrrolidone copolymer, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, hydroxyethyl cellulose, sodium carboxymethylcellulose, calcium carboxymethylcellulose, polyvinyl acetate polyethylene glycol co-polymer, a starch, maltodextrin, a sugar, sorbitol, mannitol, sucrose, gelatin, casein, a natural gum, an alginate or mxtures thereof.

13. A drug formulation as in claim 1, wherein the granule coating is water insoluble.

14. A drug formulation as in claim 13, wherein the hydrophillic polymer is selected from the group consisting of a polyether, a polyester, cellulose acetate, cellulose acetate butyrate, a polyacrylate and mixtures thereof.

15. A drug formulation as in claim 1, wherein the granule coating consists of a single layer.

16. A drug formulation as in claim 15, wherein the single layer granule coating comprises a hydrophillic polymer selected from polyvinyl pyrrolidone, polyethylene oxide or methylcellulose.

17. A drug formulation as in claim 16, wherein the hydrophillic polymer is methylcellulose.

18. A drug formulation as in claim 1, wherein the granule coating comprises a multiplicity of layers.

19. A drug formulation as in claim 18, wherein the granule coating consists of two layers.

20. A drug formulation as in claim 19, wherein the granule coating comprises an outer coating layer of methylcellulose and an inner coating layer of polyethylene oxide or polyvinyl pyrrolidone.

21. A dosage form comprising a drug formulation as in claim 1, wherein the granule comprises a low solubility therapeutic drug and wherein the low solubility therapeutic drug is topiramate.

22. A dosage form comprising

(a) a core comprising a first drug composition, a second drug composition and a push layer comprising an osmopolymer;

wherein each of the first and second drug compositions comprise granules having a substrate and a coating, said granule substrate comprising a solubilizing agent and a low solubility therapeutic drug, and said granule coating comprising a hydrophilic polymer.

(b) a semi-permeable wall surrounding the core; and

(c) an exit orifice through the semi-permeable wall for releasing the drug compositions from the dosage form over a prolonged period of time.

23. A dosage form as in claim 22, wherein the low solubility therapeutic drug is topiramate.

24. A dosage form as in claim 23, wherein the solubilizing agent is a surfactant.

25. A dosage form as in claim 24, wherein the hydrophilic polymer is methylcellulose.

26. A dosage form comprising

(a) a core comprising a drug composition, wherein the drug composition comprise granules having a substrate and a coating, said granule substrate comprising a low solubility therapeutic drug and optionally a solubilizing agent, and said granule coating comprising one or more layers, wherein each granule coating layer comprises an independently selected hydrophilic polymer;

(b) a semi-permeable wall surrounding the core; and

(c) an exit orifice through the semi-permeable wall for releasing the drug compositions from the dosage form over a prolonged period of time.

27. A dosage form as in claim 26, wherein the number of granule coating layers is selected to (a) decrease the dissolution rate of the therapeutic drug or (b) increase the time to maximum release rate of the therapeutic drug or (c) increase the period of therapeutic drug delivery or (d) decrease the magnitude of the maximum release rate of the therapeutic drug.

28. A dosage form as in claim 26, wherein the granule coating comprises one layer and wherein the hydrophilic polymer is selected to (a) decrease the dissolution rate of the therapeutic drug or (b) increase the time to maximum release rate of the therapeutic drug or (c) increase the period of therapeutic drug delivery or (d) decrease the magnitude of the maximum release rate of the therapeutic drug.

29. A dosage form as in claim 26, wherein the granule coating comprises one layer and wherein the amount of said coating is selected to (a) decrease the dissolution rate of the therapeutic drug or (b) increase the time to maximum release rate of the therapeutic drug or (c) increase the period of therapeutic drug delivery or (d) decrease the magnitude of the maximum release rate of the therapeutic drug.

30. A dosage form as in claim 26, wherein the dissolution rate of the therapeutic drug or the time to maximum release rate of the therapeutic drug or the period of therapeutic drug delivery or the magnitude of the maximum release rate of the therapeutic drug is controlled by varying one or more of (a) the number of coating granule layers, (b) the amount of each coating granule layer or (c) the hydrophilic polymer of each coating granule layer.

31. A dosage form as in claim 26, wherein the low solubility therapeutic drug is topiramate, wherein the granule coating comprises one layer and wherein the hydrophillic polymer is selected from the group consisting of methylcellulose, polyvinylpyrolidone and polyethylene oxide.

32. A dosage form as in claim 31, wherein the amount of granule coating is in the range of between about 2.5% and about 23% by weight.

33. A dosage form as in claim 26, wherein the granule coating comprises one layer and the hydrophilic polymer is selected from the group consisting of (a) methylcellulose in an amount in the range of between about 2.5% and about 13% by weight, (b) polyvinylpyrolidone in an amount in the range of between about 3% and about 23% by weight and (c) polyethylene oxide in an amount in the range of about 5% to about 15% by weight.

34. A dosage form as in claim 26, wherein the granule coating comprises one layer and the hydrophilic polymer is methylcellulose in an amount of about 3% by weight.